menu search

ADPT / Adaptive Biotechnologies Corporation (ADPT) CEO Chad Robins on Q2 2022 Results - Earnings Call Transcript

Adaptive Biotechnologies Corporation (ADPT) CEO Chad Robins on Q2 2022 Results - Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) Q2 2022 Results Conference Call August 3, 2022 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - Co-Founder, CEO Tycho Peterson - CFO Nitin Sood - CCO, MRD Sharon Benzeno - Head, Immune Medicine Conference Call Participants Brian Weinstein - William Blair Daniel Brennan - Cowen & Company David Westenberg - Piper Sandler Derik De Bruin - Bank of America Elizabeth Webster - Goldman Sachs Mark Massaro - BTIG Yuko Oku - Morgan Stanley Julia Qin - JP Morgan Operator Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter 2022 Earnings Conference Call. Read More
Posted: Aug 3 2022, 21:29
Author Name: Seeking Alpha
Views: 110617

ADPT News  

Adaptive Biotechnologies: Not Quite There Yet, Growth Looks Priced

By Seeking Alpha
September 27, 2023

Adaptive Biotechnologies: Not Quite There Yet, Growth Looks Priced

After a number of updates, there is no change in my investment rating for Adaptive Biotechnologies Corporation. Q2 FY'23 results showed mixed performa more_horizontal

Strength Seen in Adaptive Biotechnologies (ADPT): Can Its 9.5% Jump Turn into More Strength?

By Zacks Investment Research
September 27, 2023

Strength Seen in Adaptive Biotechnologies (ADPT): Can Its 9.5% Jump Turn into More Strength?

Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mi more_horizontal

3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List

By InvestorPlace
August 28, 2023

3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List

Investing in biotech stocks is challenging even when you're investing in established companies with commercially available drugs and expansive pipelin more_horizontal

5 Stocks Wall Street and ARK's Cathie Wood Love Are Trading Under $10 With Huge Upside Potential

By 24/7 Wall Street
August 26, 2023

5 Stocks Wall Street and ARK's Cathie Wood Love Are Trading Under $10 With Huge Upside Potential

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in th more_horizontal

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 2, 2023

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.33 per share in line with the Zacks Consensus Estimate. This compares to loss of more_horizontal

Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

By Zacks Investment Research
July 26, 2023

Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Adaptive Biotechnologies (ADPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prep more_horizontal

5 Sizzling ‘Strong Buy' Stocks Under $10, and ARK's Cathie Wood Loves 3 of Them

By 24/7 Wall Street
July 8, 2023

5 Sizzling ‘Strong Buy' Stocks Under $10, and ARK's Cathie Wood Loves 3 of Them

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in th more_horizontal

Adaptive Biotechnologies: Getting Closer To The 'Buy Zone'

By Seeking Alpha
July 7, 2023

Adaptive Biotechnologies: Getting Closer To The 'Buy Zone'

Shares of diagnostics and drug discovery concern Adaptive Biotechnologies Corporation have crashed over 90% as the commercial-stage concern struggles more_horizontal


Search within

Pages Search Results: